AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
4.390
+0.090 (2.09%)
At close: Aug 22, 2025, 4:00 PM
4.440
+0.050 (1.14%)
After-hours: Aug 22, 2025, 7:58 PM EDT
AbCellera Biologics Employees
AbCellera Biologics had 596 employees as of December 31, 2024. The number of employees increased by 10 or 1.71% compared to the previous year.
Employees
596
Change (1Y)
10
Growth (1Y)
1.71%
Revenue / Employee
$55,161
Profits / Employee
-$277,961
Market Cap
1.31B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 596 | 10 | 1.71% |
Dec 31, 2023 | 586 | 91 | 18.38% |
Dec 31, 2022 | 495 | 109 | 28.24% |
Dec 31, 2021 | 386 | 180 | 87.38% |
Dec 31, 2020 | 206 | 99 | 92.52% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ABCL News
- 10 days ago - AbCellera to Participate at Upcoming Investor Conferences in September - Business Wire
- 15 days ago - AbCellera Biologics Inc. (ABCL) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 15 days ago - AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms - Business Wire
- 6 weeks ago - AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
- 3 months ago - AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 - Business Wire
- 3 months ago - AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause - Business Wire
- 3 months ago - AbCellera's Microfluidic Cell Culture Patent Affirmed Valid by the U.S. Court of Appeals for the Federal Circuit - Business Wire
- 3 months ago - AbCellera Presents Positive Preclinical Data on ABCL575 at the 2025 SID Annual Meeting - Business Wire